Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLC

Second Line Capital LLC increased its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 29.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340,098 shares of the biopharmaceutical company's stock after purchasing an additional 77,288 shares during the period. Second Line Capital LLC owned approximately 0.22% of Ocular Therapeutix worth $2,904,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OCUL. Point72 Asset Management L.P. grew its stake in shares of Ocular Therapeutix by 43.9% during the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock worth $25,073,000 after purchasing an additional 895,304 shares during the period. ProShare Advisors LLC boosted its holdings in Ocular Therapeutix by 32.8% during the fourth quarter. ProShare Advisors LLC now owns 51,270 shares of the biopharmaceutical company's stock worth $438,000 after buying an additional 12,669 shares in the last quarter. Patient Square Capital LP grew its position in Ocular Therapeutix by 100.0% during the fourth quarter. Patient Square Capital LP now owns 470,919 shares of the biopharmaceutical company's stock valued at $4,022,000 after buying an additional 235,421 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ocular Therapeutix by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,422 shares of the biopharmaceutical company's stock valued at $2,309,000 after buying an additional 48,763 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth about $3,819,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on OCUL. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair began coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating for the company. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Ocular Therapeutix Stock Up 0.0%

Shares of Ocular Therapeutix stock traded up $0.00 during trading on Thursday, hitting $7.30. 347,832 shares of the stock were exchanged, compared to its average volume of 1,394,618. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm's 50-day moving average price is $7.38 and its 200 day moving average price is $8.09. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -5.56 and a beta of 1.51. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. As a group, analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard L. Md Lindstrom bought 10,000 shares of the company's stock in a transaction dated Thursday, May 8th. The stock was bought at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the acquisition, the director now owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their position. The disclosure for this purchase can be found here. Insiders own 2.30% of the company's stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.